A five-year-old girl's death in Vadodara, Gujarat, after consuming a cold-and-cough syrup has sparked a police investigation and raised significant concerns regarding drug safety in India. The deceased, identified as Dhyani Thakkar, reportedly fell ill shortly after taking the medicine, leading her aunt to suspect foul play and demand a thorough postmortem examination. This incident tragically mirrors a series of child deaths reported in other parts of India, particularly in Madhya Pradesh and Rajasthan, which were allegedly linked to contaminated cough syrups containing harmful ingredients like diethylene glycol (DEG). In response to these recurring tragedies, India's drug regulatory body, the Central Drugs Standard Control Organisation (CDSCO), has intensified its efforts to ensure drug safety. This includes launching multi-state inspections of pharmaceutical manufacturing facilities, particularly those producing cough syrups, antipyretics, and antibiotics. The CDSCO has also identified specific cough syrup brands that were found to contain DEG beyond permissible limits, leading to recalls and orders for manufacturers to cease production. Furthermore, the government has issued new advisories to restrict the use of cough syrups in young children, with recommendations suggesting they should only be given to children above five years of age and never to those under two. These measures aim to prevent future incidents and rebuild public trust in the safety of medicines manufactured in India, which is a major global drug producer. The ongoing probe in Gujarat is expected to shed light on whether the syrup consumed by the deceased child contained any harmful substances, contributing to the broader efforts to strengthen drug quality control and regulatory oversight across the country.